Vanguard Group’s Harpoon Therapeutics HARP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-880,017
Closed -$10M – 4555
2023
Q4
$10M Buy
880,017
+766,655
+676% +$6.03M ﹤0.01% 2947
2023
Q3
$457K Sell
113,362
-1,953
-2% -$14.5K ﹤0.01% 4077
2023
Q2
$819K Hold
115,315
– – ﹤0.01% 3961
2023
Q1
$858K Hold
115,315
– – ﹤0.01% 3969
2022
Q4
$837K Buy
115,315
+52
+0% +$438 ﹤0.01% 3967
2022
Q3
$1.12M Sell
115,263
-5,312
-4% -$99.1K ﹤0.01% 3970
2022
Q2
$2.3M Sell
120,575
-8,245
-6% -$214K ﹤0.01% 3745
2022
Q1
$6.4M Buy
128,820
+3,439
+3% +$178K ﹤0.01% 3399
2021
Q4
$9.47M Sell
125,381
-3,237
-3% -$221K ﹤0.01% 3240
2021
Q3
$10.2M Buy
128,618
+3,033
+2% +$305K ﹤0.01% 3235
2021
Q2
$17.4M Buy
125,585
+6,772
+6% +$1.29M ﹤0.01% 2918
2021
Q1
$24.9M Buy
118,813
+55,096
+86% +$11M ﹤0.01% 2669
2020
Q4
$10.6M Buy
63,717
+7,489
+13% +$1.16M ﹤0.01% 2963
2020
Q3
$9.6M Buy
56,228
+10,952
+24% +$1.58M ﹤0.01% 2813
2020
Q2
$7.52M Buy
45,276
+4,919
+12% +$767K ﹤0.01% 2901
2020
Q1
$4.67M Buy
40,357
+1,288
+3% +$181K ﹤0.01% 2996
2019
Q4
$5.78M Buy
39,069
+174
+0.4% +$26.4K ﹤0.01% 3126
2019
Q3
$5.31M Buy
38,895
+15,457
+66% +$2.17M ﹤0.01% 3120
2019
Q2
$3.05M Buy
23,438
+15,165
+183% +$1.76M ﹤0.01% 3339
2019
Q1
$783K Buy
+8,273
New +$1.09M ﹤0.01% 3691

Vanguard Group's HARP Position: Q1 2024 in Review

Vanguard Group sold out of Harpoon Therapeutics (HARP) in Q1 2024, closing a stake of 880,017 shares — an estimated $10M sold.

Vanguard Group first reported a position in HARP in Q1 2019 and held it in 20 quarters. The position peaked at $24.9M in Q1 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.

  • Vanguard Group reported no remaining Harpoon Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 880,017 Harpoon Therapeutics shares in Q1 2024, an estimated $10M.
  • Vanguard Group first reported a position in Harpoon Therapeutics in Q1 2019 and held it in 20 quarters.
  • Vanguard Group's Harpoon Therapeutics position peaked at $24.9M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Harpoon Therapeutics as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.